Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 7/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | XPO1 | O14980 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 3/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4559143 | 0.85 | KMT2A (0.51) | PTPN11PRKCIKMT2AMEN1LMNA | |
| SCHEMBL4559175 | 0.80 | MEN1 (0.55) | PTPN11PRKCIKMT2AMEN1LMNA | |
| SCHEMBL5686380 | 0.80 | ATR (0.48) | PTPN11XPO1MAPTATREPAS1 | |
| SCHEMBL16465324 | 0.79 | PRKCI (0.52) | PTPN11PRKCIXPO1KMT2AMEN1 | |
| SCHEMBL11298985 | 0.78 | PTPN11 (0.63) | PTPN11PRKCIXPO1KMT2AMEN1 | |
| SCHEMBL5686140 | 0.77 | SGMS2 (0.59) | GAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL5689006 | 0.77 | PTPN11 (0.47) | PTPN11GAAKMT2AMEN1 | |
| SCHEMBL5686120 | 0.77 | RAB9A (0.53) | KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL4559385 | 0.73 | MAPK10 (0.43) | PTPN11LMNAALDH1A1KDM4EMAPT | |
| SCHEMBL4559989 | 0.71 | NPC1 (0.57) | PTPN11GAAKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | PTPN11 1278/4885PRKCI 4336/4885XPO1 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.